glp-1 launch NEW FOR 2026: Medicare Bridge Program Access to eligible weight-loss medications for approximately $50/month* *Eligibility and physician approval required. Starting July 1, 2026, Medicare will a new temporary program called Glucagon-like peptide-1 - Wikipedia
Description
Standard practice includes: Baseline thyroid function tests (TSH and free T4) before initiating GLP-1 therapy Repeat testing at 812 weeks after starting treatment or after dose escalation Regular monitoring every 36 months during active weight loss Return to annual monitoring once weight is stable and thyroid function remains consistent Adjustments to levothyroxine dosing may be necessary as weight changes
Lower Risk of Cardiovascular Disease : Studies suggest that GLP-1 medications may contribute to improved heart health by reducing risk factors associated with cardiovascular diseases
Despite these issues, industry sentiment is that gaps in adoption are closing rapidly
Weight loss is just a side effect of these medications
